Research amounts aren't personal instructions
TB-500 is a lab-made piece copied from a much larger body protein.
You'll see what amounts researchers used, who received them, and why those figures can't set your care.
Which TB-500 amounts came from actual research?
TB-500 is a small copy of one body protein, and this page gives research amounts rather than a plan for you. Animal work often used the whole thymosin beta-4 protein at 6-12 milligrams for every kilogram an animal weighed. That wording adjusts for an animal's size and can't set your amount. I'd keep animal figures apart from human care.
One rat stroke test used 2-18 milligrams based on each kilogram the rat weighed [4]. A mouse muscle test used 150 micrograms of thymosin beta-4 twice weekly for six months; one gram contains a million micrograms. With about 10 trillionths of a gram, skin cells crossed more of a bare gap in a dish [3]. These results can't supply an amount for your body.
The only human figures came from full thymosin beta-4, not the small form. In Phase 1, an early safety test, 40 healthy people received 42, 140, 420, or 1260 milligrams through a vein, once and then daily for 14 days. Researchers saw some mild or moderate problems, but none made them stop raising the amount. Even at 1260 milligrams, the finding covers only the whole thymosin beta-4 protein [6].
Research figures can't become personal instructions for you. The stroke result didn't improve in a steady line as the amount rose [4]. Sellers call a bigger first amount "loading" and later smaller amounts "maintenance," yet fair human research hasn't checked that plan. Ask which material and which people support any figure your clinic gives you.
How fast does your body remove TB-500?
We don't know how fast your body would remove TB-500. Phase 1 was the first human safety step, and it used full thymosin beta-4 [6]. When researchers gave more, the blood level of that whole protein dropped more slowly. TB-500 hasn't had the same test.
Sports labs can find TB-500 and pieces left after it breaks apart. Workers first found them in blood and urine from horses [7]. Later work found them in a cell dish and in rats [14]. These tests prove the substance was present, but they can't tell you when your body has removed all of it.
If a sports test matters to you, ask the office that runs it. No study gives a sound human timetable for your test. Half-life means the time for half the substance to leave the blood; clearance means how your body removes it. The TB-500 testing page explains why neither figure is known for people.
Were the study treatments shots, skin medicine, or eye drops?
The routes that appear in the literature are intraperitoneal (predominant in rodent efficacy studies), intravenous (the human Phase 1 of full-length thymosin beta-4 and some cardiac models), and topical or ophthalmic (corneal and dermal wound and dry-eye work with full-length thymosin beta-4, including the RGN-259 formulation) [3][6]. Subcutaneous and intramuscular routes appear in community research use but not in controlled human efficacy trials.
The route matters more than community discussion usually allows. The FDA lists the LKKTETQ fragment under withdrawn nominations, with warnings about immune reactions for certain routes and missing safety information; withdrawal is not permission for a pharmacy to use the ingredient [17]. The Phase 1 human safety data are intravenous and for the full-length protein; they do not transfer to a subcutaneous fragment dosed outside a trial [6].
TB-500 is still sold as freeze-dried material labelled for lab use. As a short acetylated peptide it is more chemically robust than the full-length protein, but it remains subject to proteolysis and freeze-thaw degradation. Identity and purity of research-grade material is a recurring concern: peptide identity, purity, and correct sequence — full-length protein versus seven-mer fragment — are not guaranteed in unregulated supply, which also complicates interpreting anecdotal results [7].
Research-labelled material and prescribed medicine follow different paths; neither path closes the human evidence gap. For prescription care, a licensed U.S. clinician considers the person's health and may decide against treatment. For TB-500, Promise Peptides (mypromise.com) has begun prescribing after individual clinical review. Only patients in the U.S. can use the service; its choices differ with both the patient's state and the proposed treatment. A compounded preparation has no FDA drug approval.
